Clinuvel Pharmaceuticals (CLVLY) Stock Price, News & Analysis

Company Overview

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing treatments for patients with severe genetic, metabolic and dermatologic disorders. The company’s research is centered on melanocortin-based therapies, which are designed to help protect the skin and other tissues from damage caused by light and inflammation.

Clinuvel’s primary product is SCENESSE (afamelanotide), an implantable formulation of a synthetic analogue of alpha-melanocyte-stimulating hormone. SCENESSE is approved in several markets, including the United States, the European Union and Australia, for the prevention of phototoxic reactions in adult patients with erythropoietic protoporphyria, a rare inherited disorder that causes severe sensitivity to light.

Founded in Australia, Clinuvel serves patients and healthcare professionals across markets in North America, Europe and Australia. The company is headquartered in Melbourne and has expanded its activities internationally through regulatory, clinical and commercial operations. Philippe Wolgen has served as the company’s chief executive officer.

Key Stats

• Today's Range: $7.28 to $7.52
• 50-Day Range: $7.35 to $7.35
• 52-Week Range: $5.98 to $9.00
• Volume: 36,763 shs
• Average Volume: 3,028 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Consumer Discretionary
• Industry: Diversified Consumer Services
• Sub-Industry: Specialized Consumer Services
• Current Symbol: OTCMKTS:CLVLY
• CIK: 1290877
• Web: www.clinuvel.com
• Phone: (139) 660-4900
• Fax: N/A
• Employees: 104
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A